Back

Non-statin lipid-lowering therapy in coronary atherosclerosis regression: A meta-analysis and meta-regression.

30 August 2020 (08:30 - 08:30)
Organised by:
Congress Presentation Part of: Non-statin Treatment of Dyslipidemia Secondary Prevention ESC Premium Access ESC Congress 2020

About the speaker

Photo
Doctor Lorenzo Martin Lobo

Education Administration - Argentine Army, Buenos Aires (Argentina)

7 More presentations in this session

Presentation thumbnail
Updated treatment thresholds in the 2019 ESC/EAS dyslipidaemia guidelines substantially expand indications for statin use for primary prevention at population level: results from the Rotterdam Study
Ms J. Pavlovic (Rotterdam, NL)
Abstract Slides Video
Presentation thumbnail
Does Evolocumab use in Europe match 2019 ESC/EAS lipid guidelines? Results from the HEYMANS study
Professor K. Ray (London, GB)
Abstract Slides Video
Presentation thumbnail
REDUCE-IT: total ischemic events reduced across the full range of baseline LDL cholesterol and other key subgroups
Professor D. Bhatt (New York City, US)
Abstract Slides Video
Presentation thumbnail
REDUCE-IT: accumulation of data across prespecified interim analyses to final results
Professor B. Olshansky (Iowa City, US)
Abstract Slides Video
Presentation thumbnail
Are the results of clinical trials relevant in the real world? The applicability of REDUCE-IT to the FAST-MI Registry.
Professor J. Ferrieres (Toulouse, FR)
Abstract Slides Video

Access the full session

Session thumbnail
Non-statin Treatment of Dyslipidemia

The Event

Event poster

ESC Congress 2020

30 August 2020 08:30 CET
You may be interested in
thumbnail
Webinar
Personalised secondary prevention post-ACS: the role of biomarkers
thumbnail
Webinar
Aspirin treatment for mitigating thrombotic risk across the cardiovascular risk continuum
thumbnail
Congress Presentation
Optimal medical therapy for primary prevention

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources